Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 9 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 22%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $237,748, and 4 are calls, for a total amount of $146,349.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $340.0 for Amgen over the last 3 months.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Amgen's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Amgen's significant trades, within a strike price range of $250.0 to $340.0, over the past month.
Amgen Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BULLISH | 10/18/24 | $10.75 | $10.6 | $10.6 | $300.00 | $91.1K | 301 | 110 |
| AMGN | PUT | SWEEP | BEARISH | 03/21/25 | $19.15 | $18.95 | $19.15 | $290.00 | $67.0K | 28 | 26 |
| AMGN | CALL | TRADE | NEUTRAL | 01/16/26 | $81.0 | $78.1 | $79.51 | $250.00 | $55.6K | 60 | 7 |
| AMGN | CALL | SWEEP | BEARISH | 10/18/24 | $12.75 | $12.7 | $12.7 | $320.00 | $35.5K | 459 | 48 |
| AMGN | CALL | SWEEP | NEUTRAL | 08/16/24 | $3.05 | $2.72 | $2.88 | $340.00 | $28.8K | 1.0K | 100 |
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Amgen
- With a volume of 773,934, the price of AMGN is down -0.14% at $306.94.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 56 days.
Professional Analyst Ratings for Amgen
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $235.0.
- An analyst from Mizuho persists with their Neutral rating on Amgen, maintaining a target price of $235.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
